

BETMIGA is associated with high levels of treatment persistence, which can help improve long term outcomes.

BETMIGA is significantly better tolerated than active comparators comprising antimuscarinics therapies.²



Dry mouth
(better than
21 of 22 active
comparators)




Constipation
(better than
9 of 20 active
comparators)



Urinary retention
(better than
7 of 10 active
comparators)

BETMIGA has minimal drug-drug interactions and is safer than solifenacin and tolterodine.³⁻⁶ Persistence rates with BETMIGA were 65.8%, 52.9%, and 46.7% after 1, 2, and 3 years of treatment, respectively.⁷

Patient persistence stratified according to age



*According to a study done across five European countries.

OAB, overactive bladder.

References: 1. Reeves P, et al. Eur Urol. 2006;50:1050-1057. 2. Kelleher C, et al. Eur Urol. 2018;74:324-333. 3. Betmiga SMPC. Betmiga (mirabegron) 25 mg prolonged-release tablets. Summary of product characteristics. European Medicines Agency; 2017. Available at: https://www.ema.europa.eu/en/documents/product-information/betmiga-epar-product-information_en.pdf. Accessed 29 Oct 2021. 4. Wang J, et al. NeuroUrol Urodyn. 2019;38:22-30. 5. Baltis JA, et al. Ther Adv Urol. 2015;7:167-179. 6. Slaskin D, et al. Int Urogynecol J. 2018;29:273-283. 7. Kalo D, et al. Low Urin Tract Symptoms. 2019;11:O152-161. 8. Yeowell G, et al. BMJ open. 2018;8:e021889.